Trial Profile
Retrospective study of melphalan HDS in patients with cutaneous or uveal melanoma and liver metastases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Mar 2015
Price :
$35
*
At a glance
- Drugs Melphalan (Primary) ; Yttrium-90
- Indications Liver metastases; Malignant melanoma; Uveal melanoma
- Focus Therapeutic Use
- 31 Mar 2015 New trial record
- 27 Mar 2015 Results presented at Society of Surgical Oncology (SSO) Annual Meeting 2015, according to a Delcath Systems media release.
- 27 Mar 2015 Results published in Delcath Systems media release.